Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.

Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO, Zhou P, Karajannis MA, Giancotti FG.

Cancer Cell. 2014 Jul 14;26(1):48-60. doi: 10.1016/j.ccr.2014.05.001.

2.

Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.

Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG.

Cell. 2010 Feb 19;140(4):477-90. doi: 10.1016/j.cell.2010.01.029.

3.

Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1).

Li W, Giancotti FG.

Cell Cycle. 2010 Nov 15;9(22):4433-6. Epub 2010 Nov 15.

4.

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.

Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y.

Cancer Lett. 2017 Jan 28;385:215-224. doi: 10.1016/j.canlet.2016.10.020. Epub 2016 Oct 20.

PMID:
27773750
5.

Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression.

Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG.

Sci Signal. 2011 Aug 23;4(188):pt6. doi: 10.1126/scisignal.2002314.

PMID:
21878678
6.

The Hippo pathway member Nf2 is required for inner cell mass specification.

Cockburn K, Biechele S, Garner J, Rossant J.

Curr Biol. 2013 Jul 8;23(13):1195-201. doi: 10.1016/j.cub.2013.05.044. Epub 2013 Jun 20.

7.

Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway.

Li Y, Zhou H, Li F, Chan SW, Lin Z, Wei Z, Yang Z, Guo F, Lim CJ, Xing W, Shen Y, Hong W, Long J, Zhang M.

Cell Res. 2015 Jul;25(7):801-17. doi: 10.1038/cr.2015.69. Epub 2015 Jun 5.

8.

Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.

Miyanaga A, Masuda M, Tsuta K, Kawasaki K, Nakamura Y, Sakuma T, Asamura H, Gemma A, Yamada T.

J Thorac Oncol. 2015 May;10(5):844-51. doi: 10.1097/JTO.0000000000000493.

9.

Tumor suppressor LATS1 is a negative regulator of oncogene YAP.

Hao Y, Chun A, Cheung K, Rashidi B, Yang X.

J Biol Chem. 2008 Feb 29;283(9):5496-509. Epub 2007 Dec 24.

10.

Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent.

Hikasa H, Sekido Y, Suzuki A.

Cell Rep. 2016 Mar 29;14(12):2950-61. doi: 10.1016/j.celrep.2016.02.075. Epub 2016 Mar 17.

11.

RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.

Jang JW, Kim MK, Lee YS, Lee JW, Kim DM, Song SH, Lee JY, Choi BY, Min B, Chi XZ, Bae SC.

Oncogene. 2017 Feb 16;36(7):999-1011. doi: 10.1038/onc.2016.266. Epub 2016 Jul 18.

PMID:
27425596
12.

The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.

Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I, Barczyk M, Hanemann CO.

Oncogene. 2016 Jun 30;35(26):3443-53. doi: 10.1038/onc.2015.404. Epub 2015 Nov 9.

13.
14.

A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.

Moroishi T, Park HW, Qin B, Chen Q, Meng Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D, Guan KL.

Genes Dev. 2015 Jun 15;29(12):1271-84. doi: 10.1101/gad.262816.115.

15.

Merlin, a multi-suppressor from cell membrane to the nucleus.

Zhou L, Hanemann CO.

FEBS Lett. 2012 May 21;586(10):1403-8. doi: 10.1016/j.febslet.2012.03.016. Epub 2012 Mar 21. Review.

16.

Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.

Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T.

Mol Cell. 2003 Oct;12(4):841-9.

17.

Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations.

Sheffield BS, Lorette J, Shen Y, Marra MA, Churg A.

Arch Pathol Lab Med. 2016 May;140(5):391. doi: 10.5858/arpa.2015-0508-LE. No abstract available.

PMID:
27128293
18.

Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2.

Zhang S, Chen Q, Liu Q, Li Y, Sun X, Hong L, Ji S, Liu C, Geng J, Zhang W, Lu Z, Yin ZY, Zeng Y, Lin KH, Wu Q, Li Q, Nakayama K, Nakayama KI, Deng X, Johnson RL, Zhu L, Gao D, Chen L, Zhou D.

Cancer Cell. 2017 May 8;31(5):669-684.e7. doi: 10.1016/j.ccell.2017.04.004.

PMID:
28486106
19.

Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.

Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, Sun Y, Hudmon A, Wells CD.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17368-73. doi: 10.1073/pnas.1308236110. Epub 2013 Oct 7.

20.

Molecular insights into NF2/Merlin tumor suppressor function.

Cooper J, Giancotti FG.

FEBS Lett. 2014 Aug 19;588(16):2743-52. doi: 10.1016/j.febslet.2014.04.001. Epub 2014 Apr 12. Review.

Supplemental Content

Support Center